Treatment of Well-Differentiated Gastric Neuroendocrine Tumor (NET)

This protocol applies to well-differentiated gastric neuroendocrine tumor (NET) of the gastrointestinal tract. It does not apply to poorly differentiated neuroendocrine carcinoma (NEC), which represents a distinct and separate diagnostic category.

Per WHO Classification criteria for both Endocrine Organs and Digestive System tumors, neuroendocrine neoplasms are categorised as either well-differentiated NETs or poorly differentiated NECs. Correct classification is essential before any treatment pathway is applied.

For well-differentiated gastric NET, management may include somatostatin analogue therapy — such as octreotide or lanreotide — addressing both hormonal symptom control and tumor control. The full evidence-based regimen and sequencing are available in the complete protocol.